Continuing Education Information for Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
© 2019 Harborside™
Optimizing Treatment and Improving Outcomes
for Patients With Acute Myeloid Leukemia:
A Guide for Advanced Practitioners
Table of Contents
- Acute Myeloid Leukemia: An Ever-Changing Disease
- Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
- The Role of the Advanced Practitioner in Enhancing Outcomes
- Appendix: Key Information on Newly Approved AML Drugs
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Harborside Medical Education
Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.
Release date: December 20, 2019
Expiration date: December 19, 2020
Estimated time to complete activity: 1.0 hour
Certified for CE by:
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Journal of the Advanced Practitioner in Oncology
94 North Woodhull Road
Huntington, NY 11743
© 2019, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
This certified activity is supported by educational grants from Agios Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.
Nancy Nix, PharmD, BCPS, BCOP, Ballad Health, Johnson City, Tennessee
Allyson Price, MPAS, PA-C, MD Anderson Cancer Center, Houston, Texas
This activity is designed for advanced practitioners (e.g., nurse practitioners, physician assistants, advanced practice nurses, and oncology pharmacists) who treat patients with acute myeloid leukemia.
After completing this educational activity, participants should be able to:
- Interpret clinical data regarding the efficacy and safety of approved therapeutic options for acute myeloid leukemia
- Assess risk-stratified approaches for development of treatment plans in accordance with best practices and evidence-based recommendations
- Plan strategies to assess minimal residual response
- Formulate plans to monitor for and manage treatment-related adverse events
- Evaluate clinical data from trials in progress for emerging agents
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hours.
Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-19-143-H01-P. This program is designated for up to 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit.
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Dr. Nix has served on the speakers bureau for Coherus BioSciences and advisory boards for Bristol-Myers Squibb, Genentech, Puma, Sandoz, and Teva.
Ms. Price has served as a consultant for Agios and on an advisory board for Daiichi Sankyo.
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER
Charles Willis, Director of Continuing Education, consults for Pfizer, Inc. All other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has nothing to disclose.
Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.
Lorinda Coombs, PhD, FNP-BC, AOCNP®, has served on an advisory board for Alexion Pharmaceuticals.
Andrea Primeau, PhD, MBA, has nothing to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food & Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.